Raynaud phenomenon articles from across Nature Portfolio

Raynaud phenomenon and digital ulcers are some of the most common and difficult to treat manifestations of systemic sclerosis. In this Review, the authors outline how to assess and treat these conditions, and also discuss unmet clinical needs.

Systemic sclerosis is an autoimmune disease characterized by vasculopathy-induced fibrosis of the skin and organs that can be life-threatening. This PrimeView summarizes the mechanisms underlying the condition, how patients are diagnosed and the quality of life of patients.

Systemic sclerosis is an autoimmune disease characterized by vasculopathy-induced fibrosis of the skin and organs that can be life-threatening. Varga and colleagues describe the current views of pathogenesis and treatment, and present an outlook for the future.

This article places Raynaud phenomenon in the context of a mechanistic understanding of cutaneous vasoconstrictive and thermoregulatory processes, describing how these processes might regulate the pathogenesis of Raynaud phenomenon and ultimately inform new approaches to its treatment.

The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α_2A-adrenoceptors, and suggests opportunities for drug repurposing.

Early identification of secondary Raynaud phenomenon is essential to treat the underlying disease—most frequently systemic sclerosis (SSc). Integrated therapeutic approaches and monitoring systems that offer improved modalities of care feature in the new best practice recommendations for the treatment of digital vasculopathy in SSc.